DEVICE FOR CONTROLLED ADMINISTRATION OF A LIQUID SOLUTION TO NASAL CAVITIES AND PARANASAL SINUSES
20240000658 ยท 2024-01-04
Inventors
Cpc classification
A61M31/00
HUMAN NECESSITIES
International classification
Abstract
Devices for controlled administration of liquid solutions to nasal cavities and paranasal sinuses are disclosed. The proposed devices comprise an external housing defining an inner space and having a proximal and a distal end. The external housing comprises an air system for injecting air to a nostril plugs assembly; a pump system for pumping the liquid solution to the nasal cavities; a removable cartridge holding the liquid solution, connected to the pump system; and a nostril plugs system removably connected to the pump system. The nostril plugs system comprises a two-line resilient tube; a plug-in system connected to one of the resilient tube; and a nostril plugs assembly connected to the other end of the resilient tube. The proposed devices may be used for the treatment of respiratory diseases including the respiratory syndrome coronavirus 2 (SARS-CoV-2).
Claims
1. A device for controlled administration of a liquid solution to nasal cavities and paranasal sinuses of a user, comprising: an external housing (1) defining an inner space and having a proximal end and a distal end, the external housing comprising: an air system (2) for injecting air to a nostril plugs assembly (9); a pump system (3) for pumping the liquid solution to the nasal cavities and connected to the air system (2) by means of a resilient tube (6); a cartridge (4) holding the liquid solution, removably connected to the pump system (3) at the proximal end of the external housing (1); and a nostril plugs system (5) removably connected to the pump system (3) at the distal end of the external housing (1) and comprising: a two-line resilient tube (7) having a proximal end and a distal end; a plug-in system (8) connected to the proximal end of the resilient tube (7); and a nostril plugs assembly (9) connected to the distal end of the resilient tube (7).
2. The device according to claim 1, wherein the air system (2) comprises: an air bulb (20); an air release valve (21) connected to the air bulb (20) through an air bulb base (22) and comprising: a valve cover (23); a valve plunger (24); a valve cover sealing means (25); a valve plunger sealing means (26) a first spring means (27) that applies a constant pressure holding the valve plunger sealing means (26) and allows air flow in only one direction, preventing reverse flow; an actuator (28) activated by the user's pressure and comprising and an actuator sealing means (29); a second spring means (30); and an air outlet (31) for connection to the silicone tube (6).
3. The device according to claim 1, wherein the pump system (3) comprises: a cylinder (10); a spring means (11) arranged around the outside of the cylinder (10); a pump nozzle (12) for connection with the cartridge (4) comprising sealing means (13); a hollow piston (14) which is movable in the cylinder (10) and comprises sealing means (13); a valve member (15) which is guided by the hollow piston and is mounted so as to be axially movable with the piston (14); and a pump base (16) comprising an air inlet port (17) connected to an air discharge plug (18) to channel the air coming from the air system (2) and a liquid discharge plug (19) to channel the liquid from the cartridge (4).
4. The device according to claim 1, wherein the external housing (1) is made of a plastic material.
5. The device according to claim 1, wherein the external housing (1) holds the pump system (2) and the air system (3) by means of a snap-fit mechanism (48) through a subframe set (49).
6. The device according to claim 1, wherein the cartridge (4) comprises: a container (32) comprising the liquid solution; a hollow cylindrical piston (33) arranged inside the container (32); a one-way valve mechanism (34); a container lid (35); a pump connection mechanism (36); and a cartridge lid (37) to lock the container (32).
7. The device according to claim 6, wherein the container (32) has a content of 50 ml of liquid solution.
8. The device according to claim 6, wherein the cartridge lid (37) comprises a safety mechanism (38) to protect the connection area of the cartridge from dirt and to certify that the cartridge has not been used before.
9. The device according to claim 1, wherein the two-line silicone tube (7) has an air line (50) to inject air to the nostril plugs assembly (9) and a liquid line (51) to deliver the liquid solution from the cartridge (4) to the nasal cavities.
10. The device according to claim 1, wherein the plug-in system (8) comprises: two plastic components (44) that are designed to snap-fit into a socket female plug (45) of the external housing (1); a notch (46) for correct positioning of the plug system in the liquid and air discharge plugs (18, 19); and a plastic accessory (47) for connection of the plug-in system to the silicone tube (7).
11. The device according to claim 1, wherein the nostril plugs assembly (9) comprises: a plastic accessory (39) to connect the nostril plugs assembly to the silicone tube (7); a nostril plugs component (40); two Y-shaped internal components (39a, 39b) that distribute the liquid solution and air in the nostril plugs component (40); and a support (41) that holds all the nostril plugs assembly components together by means of a snap-fit technology or ultrasonic bonding and creates mechanical tightening to create an airtight chamber inside.
12. The device according to claim 11, wherein the nostril plugs component (40) has two bell-shaped expandable portions (42, 43).
13. The device according to claim 12, wherein the two bell-shaped expandable portions (42, 43) are arranged at an angle (a) to offer perfect adaptation and ergonomics to the human nose and offer comfort and safety in the nasal cavity, the angle being between 130 degrees and 140 degrees, most preferably 135 degrees.
14. The device according to claim 12, wherein the two expandable bell-shaped portions (42, 43) of the nostril plugs component (40) comprise a network of internal tubes that allow the expandable portions to swell with the air coming from the air system and create an airtight lock with the user's nostrils.
15. A cartridge holding a liquid solution for connection to a pump system of a device for controlled administration of a liquid solution to nasal cavities and paranasal sinuses of a user, comprising: a container (32) comprising the liquid solution; a hollow cylindrical piston (33) arranged inside the container (32); a one-way valve mechanism (34); a container lid (35); a pump connection mechanism (36); and a cartridge lid (37) to lock the container (32): and a safety mechanism (38) to protect the connection area of the cartridge from dirt and to certify that the cartridge has not been used before.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Non-limiting examples of the present disclosure will be described in the following, with reference to the appended drawings, in which:
[0036]
[0037]
[0038]
[0039]
[0040]
[0041]
[0042]
[0043]
[0044]
[0045]
[0046]
[0047]
[0048]
[0049]
DETAILED DESCRIPTION OF THE INVENTION
[0050]
[0051] The external housing 1 defines an inner space comprising an air system 2 for injecting air to a nostril plugs assembly 9 and a pump system 3 for pumping a liquid solution to the nasal cavities.
[0052] According to a preferred embodiment of the present invention, the external housing 1 is made of a plastic material.
[0053] As shown in
[0054]
[0055] In a preferred embodiment, the valve plunger 24 is shaped like a ball and the actuator sealing means 29 is an O-ring.
[0056] In a preferred embodiment, all of the air system 2 components are made of plastic and have a special design that aims to create the right position for the air bulb 20 and the actuator 28 to help the user ergonomically during the treatment.
[0057] The air system 2 is built in such a way that the device doesn't comprise any electronic or electrical parts and is completely autonomous.
[0058]
[0059] As shown in
[0060] The cartridge lid 37 comprises a safety lid 38 to protect the connection area of the cartridge from dirt and to certify that the cartridge has not been used before.
[0061] The container 32 holds approximately between 50 ml and 150 ml, which according to medical research is the quantity of fluid required to fill both the nasal and the paranasal cavities of a user or patient. Therefore, this is the required quantity of fluid to deliver a proper treatment of this kind.
[0062] In a preferred embodiment, the container holds 50 ml of a liquid solution.
[0063] As shown in
[0064] As shown in
[0065] As shown in
[0066] The nostril plugs assembly 9 comprises a plastic accessory 39 to connect the nostril plugs assembly to the tube 7; two Y-shaped internal components 39a, 39b that distribute the liquid solution and air in a nostril plugs component 40; and a support 41 that holds all the nostril plugs assembly components together by means of a snap-fit technology and creates mechanical tightening to create an airtight chamber inside.
[0067] The nostril plugs component 40 has two bell-shaped expandable portions 42, 43, as shown in
[0068] In a preferred embodiment of the present invention, the angle is between 130 degrees and 140 degrees, and most preferably 135 degrees.
[0069] The two expandable bell-shaped portions 42, 43 of the nostril plugs component 40 comprise a network of internal tubes that allow the expandable portions to swell with the air coming from the air system and create an airtight lock with the user's nostrils.
[0070] The two-line resilient tube 7 has an air line 50 to inject air to the nostril plugs component 40 and a liquid line 51 to deliver the liquid solution from the cartridge 4 to the nasal cavities through an orifice 52 of the two bell-shaped expandable portions of the nostril plugs component 40.
[0071] As shown in
[0072]
[0073]
[0074] The perfectly tolerable use of the device may give the user the possibility to use the therapeutic process with ease, even when at work or while sitting on a couch (e.g. while watching TV), for as long as a user wants, providing an effective method. The friendliness of a prolonged therapeutic use provides the necessary time for the therapeutic solution to act during a necessary time to maximize the therapeutic result in the nasal and paranasal chambers. The time may range between five (5) and fifteen (15) minutes. However, in some cases even longer periods of half an hour may be beneficial so that the therapeutic effect of the liquid may take place.
[0075] The end result may provide an effective solution desired and long sought after by the medical community and users. It may be made possible by the combination of characteristics of the proposed devices and/or methods. That is, the devices may provide a complete sealing of the nostrils, in some implementations thus provoking the swallowing reflex when sufficient liquid is introduced in the nostrils.
[0076] Furthermore, the way that the nasal cavities are sealed may not be a simple sealing but may produce some further effects: The expansion of the intranasal part of the device in the nostril may be disposed to push outwards the alar sidewalls of the nostrils which results in a widening of the nasal vestibule, and in some implementations thus freeing the nasal conchae and revealing the ducts of the paranasal sinuses which may facilitate the introduction of liquid to the paranasal sinuses.
[0077] Moreover, proper obstruction of both nostrils provided by the use of the proposed devices and/or methods, may allow the solution to remain in the nostrils and in the paranasal sinuses for as long as the user may wish, thereby providing the necessary time so that the therapeutic and/or cell-regenerative and/or healing properties of the medicine or of the saline (sea water) or of the extracts of aromatic plants to give results.
[0078] Therefore, the therapeutic result for the user or patient may depend on the proper application of the process that is provided by the proposed devices. It is also mentioned that an application of the solution to the nostrils may be performed in a soft and totally controllable manner and in small doses. This may in some applications be achieved by the cartridge construction that may provide solution under pressure in such a way that with each application (pressure) only a small controlled quantity may be provided to both nostrils.
[0079] While the examples have been described in detail in the foregoing description, the same is to be considered illustrative and not restrictive in character, being understood that only some examples have been shown and described and that all changes and modifications that come within the spirit of the examples are desired to be protected. While said particular examples of the present disclosure have been described, it would be obvious to those skilled in the art that various other changes and modifications may be made without departing from the spirit and scope of the disclosure. It is therefore intended to cover in the appended claims all such changes and modifications are within the scope of the disclosure.
REFERENCES
[0080] 1. Lirong Zou et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients, N Engl J Med 2020; 382:1177-1179, DOI: 10.1056/NEJMc2001737. [0081] 2. Gengler I, Wang J C, Speth M M, Sedaghat A R. Sinonasal pathophysiology of SARS-CoV-2 and COVID-19: A systematic review of the current evidence. Laryngoscope Investigative Otolaryngology. 2020; 1-6. https://doi.org/10.1002/lio2.384. [0082] 3. Rafael R. G., Machado, Talita Glaser, Danielle B. Araujo, Lyvia Lintzmaier Petiz, Danielle B. L. Oliveira, Giuliana S. Durigon, Alessandra L. Leal, Joo Renato R. Pinho, Luis Carlos S. Ferreira, Henning Ulrich, Edison L. Durigon, Cristiane R. Guzzo, Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay. BioR.sub.Xiv, doi: https://doi.org/10.1101/2020.08.04.235549 [0083] 4. Sandeep Ramalingam, Baiyi Cai, Junsheng Wong, Matthew Twomey, Rui Chen, Rebecca M. Fu, Toby Boote, Hugh McCaughan, Samantha J. Griffiths, Jrgen G. Haas, Antiviral innate immune response in non-myeloid cells is augmented by chloride ions via an increase in intracellular hypochlorous acid level, Scientific Reports (2018) 8:13630|DOI:10.1038/s41598-018-31936-y (www.nature.com/scientificreports). [0084] 5. Sandeep Ramalingam, Catriona Graham, Jenny Dove, Lynn Morrice, Aziz Sheikh, A pilot, open labelled, randomised controlled trial of hypertonic saline nasal irrigation and gargling for the common cold, Scientific Reports (2019) 9:1015 https://doi.org/10.1038/s41598-018-37703-3 (www.nature.com/scientificreports).